Imagin Medical Valuation
Is DPD3 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of DPD3 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate DPD3's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate DPD3's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for DPD3?
Key metric: As DPD3 is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.
| What is DPD3's PB Ratio? | |
|---|---|
| PB Ratio | -0.01x |
| Book | -CA$11.96m |
| Market Cap | CA$162.45k |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | n/a |
| Enterprise Value/EBITDA | -4.9x |
| PEG Ratio | n/a |
Price to Book Ratio vs Peers
How does DPD3's PB Ratio compare to its peers?
| Company | Forward PB | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 1.3x | ||
AUG Audientes | 3.9x | n/a | €6.9m |
HT6 Learning 2 Sleep L2S | 0.03x | n/a | €85.9k |
GME Geratherm Medical | 0.7x | 89.5% | €15.0m |
NN6 NanoRepro | 0.5x | n/a | €19.6m |
DPD3 Imagin Medical | n/a | n/a | €162.5k |
Price-To-Book vs Peers: DPD3 has negative equity and a Price-To-Book Ratio (-0x) compared to the peer average (1x).
Price to Book Ratio vs Industry
How does DPD3's PB Ratio compare vs other companies in the DE Medical Equipment Industry?
Price-To-Book vs Industry: DPD3 has negative equity and a Price-To-Book Ratio (-0x) compared to the European Medical Equipment industry average (2x).
Price to Book Ratio vs Fair Ratio
What is DPD3's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PB Ratio | -0.01x |
| Fair PB Ratio | n/a |
Price-To-Book vs Fair Ratio: Insufficient data to calculate DPD3's Price-To-Book Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
LNA Santé
€244.4m
Engages in the management and operation of health establishments.
2N3
€23.25
7D
-5.5%
1Y
18.9%
Shandong Weigao Group Medical Polymer
HK$20.1b
Engages in the research and development, production, wholesale, and sale of medical devices in the People’s Republic of China.
UK2
HK$0.52
7D
-8.8%
1Y
-37.3%
Top Glove Corporation Bhd
RM 7.8b
An investment holding company, manufactures, trades in, and sells gloves in Malaysia, Thailand, the People’s Republic of China, and internationally.
5OU
RM 0.98
7D
0.5%
1Y
-82.5%